Chapters

Transcript

Video

SABCS 2022: Sara Tolaney, MD, MPH

Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and trastuzumab confirm excellent long-term outcomes for small, node-negative HER2-positive breast cancer.

View Full Profile

ADVERTISEMENT

Related Videos